Compare Crispr Therapeutics AG (CRSP) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs State Street SPDR S&P Homebuilders ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B). The key difference: Crispr Therapeutics AG is far larger — about 3.3× State Street SPDR S&P Homebuilders ETF's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| CRSP | XHB | |
|---|---|---|
Market Cap | $4.88B | $1.49B |
Volume | 2,861,747 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.97 | $121.36 |
52-Week Low | $44.34 | $94.77 |
Typical Hold Time | 77 Days | 33 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
XHB (SPDR S&P Homebuilders ETF) trades at $95.66, up 0.81% with a bearish technical signal from moving averages. The ETF faces headwinds from rising mortgage rates above 7% but shows potential catalysts from new housing legislation and institutional interest. Recent news highlights mixed housing data with June new home sales rising 1.6% while existing home sales declined 2.4%, creating uncertainty in the housing sector.
The homebuilder ETF presents a contrarian opportunity amid sector weakness, with historical valuation signals suggesting potential rebounds. Key risks include persistent high mortgage rates and housing affordability challenges, while positive catalysts include institutional accumulation and government housing support measures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
